
Commentary|Videos|November 23, 2024
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Author(s)J. Bradley Elder, MD
J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.
Advertisement
J. Bradley Elder, MD, director, Neurosurgical Oncology; professor, Department of Neurological Surgery, the Brain and Spine Tumor Center, The Ohio State University Wexner Medical Center, discusses
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































